A druglikeness-first approach that searches trillion-molecule spaces to deliver lead-ready compounds
The Drug Discovery Bottleneck
After nearly 25 years in drug discovery, I’ve watched the same pattern repeat. Programs identify modest hits, then spend five to seven years attempting to optimize toward a clinical candidate—most of which never materialize. The failures are rarely due to target affinity. Instead, they stem from ADME, PK, toxicity, and developability issues that surface late, when the cost of failure is highest.
Yet modern drug discovery—both experimental and computational—remains overwhelmingly affinity-first.
Computationally, this constraint no longer applies.
So, we inverted the problem.
Druglikeness First, Not as a Filter
Denovicon’s quantum physics-driven generative AI for multi-objective optimization (MOO) of small-molecule drugs searches trillion-molecule, chemically diverse spaces for molecules that are drug-like from the outset, optimized simultaneously across multiple developability-relevant properties before target matching.
This is not a sequential workflow and not a post-hoc filtering step.
Instead, drug-relevant constraints are embedded directly into the optimization process, enabling the platform to identify molecules that satisfy competing requirements in a single, unified search.
The result is lead-quality molecules, not modest hits—and chemistry that medicinal teams can interrogate and advance with confidence.
Interpretable Chemistry at Scale
Unlike many generative approaches that rely on opaque latent representations, Denovicon’s platform is designed to produce outputs that support chemical interpretability and rational follow-up, enabling clear structure–property and structure–activity reasoning during optimization.
This allows discovery teams to understand why a molecule works, not just that it works—reducing downstream risk and accelerating decision-making.
Improved Synthesizability by Design
One of the most common limitations of generative AI in drug discovery is that computationally attractive molecules are often synthetically impractical. Many platforms treat synthesizability as a downstream filter—generate candidates first, then discard what can’t be made. By that point, much of the useful chemical space has been filtered away.
Denovicon’s platform optimizes for improved synthesizability as part of the multi-objective optimization itself—alongside the rest of the desired properties. The result is molecules that are not only predicted to have favorable drug properties but are also accessible through established chemistries.
Customized to Your Program
No two drug discovery programs share the same constraints. Teams bring existing chemical libraries, established SAR, and years of institutional knowledge.
Denovicon’s platform is customizable to leverage all these aspects. The optimization operates within real-world program constraints rather than generating molecules in a vacuum to ensure actionable items within an existing discovery program.
Validated in a Real Drug Discovery Program
Denovicon’s approach has already been validated in practice. Using its AI- and physics-based platform, Denovicon delivered a PARP7 inhibitor with greater than 2,000× selectivity over both PARP1 and PARP2 — compared to the pan-PARP clinical compound RBN-2397 (PARP7/PARP1/PARP2 = 3 nM/37 nM/17 nM).
The new multi-objective optimization platform builds on this proven foundation, extending its ability to search larger chemical spaces while optimizing across all key drug-relevant properties simultaneously.
Built for Scale, Ready for the Future
The platform is production-ready today, while architected for future compatibility with emerging computational hardware—allowing Denovicon to take advantage of new acceleration technologies as they mature, without changing the underlying discovery workflow.
About Denovicon Therapeutics
Denovicon Therapeutics is a biotechnology company developing AI- and physics-based computational platforms to transform small-molecule drug discovery by delivering lead-ready compounds through scalable, interpretable multi-objective optimization.